Akcea Therapeutics Inc (NASDAQ:AKCA) price target lowered to $25.00 by Stifel Nicolaus

Analyst Ratings For Akcea Therapeutics Inc (NASDAQ:AKCA)

Story continues below

Today, Stifel Nicolaus lowered its price target on Akcea Therapeutics Inc (NASDAQ:AKCA) to $25.00 per share.

There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Akcea Therapeutics Inc (NASDAQ:AKCA) is Hold with a consensus target price of $37.00 per share, a potential 49.86% upside.

Some recent analyst ratings include

  • 8/8/2018-Akcea Therapeutics Inc (NASDAQ:AKCA) gets downgraded to Hold by UBS Group
  • 2/27/2018-Akcea Therapeutics Inc (NASDAQ:AKCA) gets downgraded to Market Perform by Cowen

Recent Insider Trading Activity For Akcea Therapeutics Inc (NASDAQ:AKCA)
Akcea Therapeutics Inc (NASDAQ:AKCA) has insider ownership of 3.88% and institutional ownership of 26.58%.

  • On 4/17/2018 Ionis Pharmaceuticals Inc, Major Shareholder, bought 10,666,666 with an average share price of $18.75 per share and the total transaction amounting to $199,999,987.50.
  • On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.

About Akcea Therapeutics Inc (NASDAQ:AKCA)
Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Recent Trading Activity for Akcea Therapeutics Inc (NASDAQ:AKCA)
Shares of Akcea Therapeutics Inc closed the previous trading session at 24,43 −8,69 26,24 % with shares trading hands.

An ad to help with our costs